Max Robotics — Global Service Robot Directory + US Certification

About

Takeshi Omori is a leading figure in the surgical treatment of gastric cancer, with a research focus on the comparative effectiveness and technical refinement of robotic versus laparoscopic gastrectomy. His major contributions include demonstrating through propensity score-matched analyses that robotic gastrectomy offers superior perioperative outcomes, such as reduced pancreatic fistula rates—particularly in patients with challenging anatomy like a small pancreas-left gastric artery angle. Omori is the principal investigator of the landmark JCOG1907 MONA LISA study, a phase III randomized controlled trial designed to establish the superiority of robot-assisted gastrectomy over the laparoscopic standard for clinical stage T1-4aN0-3 gastric cancer. His work has been cited over 120 times, with his 2022 comparison study alone garnering 54 citations. Beyond comparative effectiveness, Omori has pioneered advanced techniques, including the first completely robotic total gastrectomy with thrombectomy and portal vein reconstruction for gastric cancer with portal vein tumor thrombus, and has developed the intracorporeal triangular anastomotic technique to enhance safety and simplicity in robotic distal gastrectomy. His clinical acumen extends to real-world pharmacovigilance, as evidenced by his reporting of zolbetuximab-induced protein-losing enteropathy. Omori’s leadership in JCOG1809, a phase II trial evaluating laparoscopic/robotic total gastrectomy with spleen-preserving splenic hilar dissection, further underscores his commitment to minimizing invasiveness while maximizing oncologic outcomes.